Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 6/20 | 0.46 |
| ▸ | FPR2 | P25090 | 6/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123704 | 0.90 | DRD2 (0.53) | ACHEBACE1DRD2CD274 | |
| SCHEMBL4119993 | 0.89 | KDM4E (0.51) | ACHEBACE1DRD2KDM4EALDH1A1 | |
| SCHEMBL4114315 | 0.88 | EPHX2 (0.50) | FPR3FPR2ACHEBACE1DRD2 | |
| SCHEMBL4115221 | 0.83 | FPR3 (0.48) | FPR3FPR2TDP1 | |
| SCHEMBL4107385 | 0.82 | ALDH1A1 (0.53) | ACHEBACE1DRD2KDM4EALDH1A1 | |
| SCHEMBL4115223 | 0.81 | FPR3 (0.46) | FPR3FPR2ALDH1A1TDP1 | |
| SCHEMBL4120380 | 0.80 | ALDH1A1 (0.45) | ACHEBACE1DRD2KDM4EALDH1A1 | |
| SCHEMBL4126336 | 0.78 | CNR1 (0.50) | FPR3FPR2L3MBTL1TNIK | |
| SCHEMBL4129069 | 0.76 | DRD2 (0.45) | FPR3FPR2DRD2CD274CASR | |
| SCHEMBL4118371 | 0.74 | EPHX2 (0.54) | FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | FPR3 3043/4885FPR2 839/4885ACHE 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.